AUG 27 2004

510(k) Summary 8.0

B. Braun Medical Inc. **SUBMITTER:**

901 Marcon Boulevard Allentown, PA 18109-9341 (610) 266-0500, ext. 2516

Contact: Jennifer A. Pung, Senior Analyst, Regulatory Affairs

B. Braun Bicarbonate Dialysate **DEVICE NAME:**

Bicarbonate Dialysate COMMON OR USUAL

NAME:

Class II, 21 CFR § 876.5820, Hemodialysis System and **DEVICE**

CLASSIFICATION: Accessories (Product Code KPO)

Gambro Renal Products - Gambro PrismaSate Dialysis PREDICATE DEVICE:

Solutions for Continuous Renal Replacement Therapy

(K013448)

The B. Braun Bicarbonate Dialysate Solutions are a family of **DESCRIPTION:**

sterile, non-pyrogenic, bicarbonate dialysate solutions. The solutions will be provided in flexible two-chamber bags, with bicarbonate solution in one chamber and electrolyte solution in the other chamber. The chambers are separated by a peel seam. The 5,000 mL ready-to-use solution is obtained by pressing on the small chamber of the bag until the peel seam opens, and then rocking the bag back and forth to mix the contents.

B. Braun Bicarbonate Dialysate is indicated for use with renal **INTENDED USE:**

replacement therapy systems that utilize sterile bicarbonate

dialysate.

The B. Braun Bicarbonate Dialysate has a similar composition SUBSTANTIAL **EQUIVALENCE:**

range, container/closure system, and indications for use as the PrismaSate Dialysis Solutions marketed by Gambro under the

510(k) Premarket Notification K013448.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 27 2004

Ms. Jennifer A. Pung Senior Analyst, Regulatory Affairs B. Braun Medical, Inc. 901 Marcon Blvd. ALLENTOWN PA 18109-9341

Re: K041683

Trade/Device Name: B. Braun Bicarbonate Dialysate

Regulation Number: 21 CFR §876.5820

Regulation Name: Hemodialysis system and accessories

Regulatory Class: II Product Code: 78 KPO Dated: June 18, 2004 Received: June 21, 2004

Dear Ms. Pung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

2.0 Indications	for Use Statement		Page	_1	of1
510(k) Number (if ki	nown): <u>K04/6</u>	83			
Device Name:	B. Braun Bicarbonate	Dialysate			
Indications For Use:		**			
B. Braun Bicarbona that utilize sterile bi	te Dialysate is indicated carbonate dialysate.	for use with r	enal repla	cement	therapy systems
Prescription Use(Per 21 CFR 801.1	X 109)	OR	Over-Th	e-Cour	iter Use
(PLEASE DO NO NEEDED)	OT WRITE BELOW TH	IIS LINE - CO	ONTINUE	E ON A	NOTHER PAGE IF
Concurrence of C	DRH, Office of Device I	Evaluation (O	DE)		
	Dan	id a. Sy	ng~~		
	(Division Sig Division of R and Radiolog 510(k) Numb	eproductive, A gical Devices	bdominal, KOH(82	